AG2R LA Mondiale Gestion D Actifs Has $1.55 Million Stake in Humana Inc. $HUM

Key Points

• AG2R LA Mondiale Gestion D Actifs increased its stake in Humana Inc. by 17.2% during the second quarter, reaching a total value of $1.55 million at the end of the reporting period.
• Humana's stock price opened at $290.66 and has shown significant fluctuation with a fifty-two week low of $206.87 and a high of $315.35.
• The company recently announced a quarterly dividend of $0.885, reflecting an annualized yield of 1.2% with a payout ratio of 27.17%.

AG2R LA Mondiale Gestion D Actifs boosted its stake in Humana Inc. (NYSE:HUM - Free Report) by 17.2% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,358 shares of the insurance provider's stock after purchasing an additional 933 shares during the period. AG2R LA Mondiale Gestion D Actifs' holdings in Humana were worth $1,554,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of HUM. Revolve Wealth Partners LLC acquired a new stake in Humana during the 4th quarter worth about $202,000. GAMMA Investing LLC grew its holdings in Humana by 54.9% during the 1st quarter. GAMMA Investing LLC now owns 2,952 shares of the insurance provider's stock worth $781,000 after acquiring an additional 1,046 shares during the period. Janney Montgomery Scott LLC acquired a new stake in Humana during the 1st quarter worth about $1,309,000. Cambridge Investment Research Advisors Inc. grew its holdings in Humana by 3.2% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 4,608 shares of the insurance provider's stock worth $1,219,000 after acquiring an additional 145 shares during the period. Finally, Robeco Institutional Asset Management B.V. grew its holdings in Humana by 502.0% during the 1st quarter. Robeco Institutional Asset Management B.V. now owns 48,541 shares of the insurance provider's stock worth $12,844,000 after acquiring an additional 40,478 shares during the period. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on HUM. Wells Fargo & Company increased their price target on Humana from $344.00 to $347.00 and gave the stock an "overweight" rating in a report on Tuesday, October 7th. Wall Street Zen downgraded Humana from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Wolfe Research raised their target price on Humana from $283.00 to $313.00 and gave the company an "outperform" rating in a research note on Monday, October 6th. Royal Bank Of Canada raised their target price on Humana from $283.00 to $322.00 and gave the company an "outperform" rating in a research note on Thursday, August 21st. Finally, Robert W. Baird reduced their target price on Humana from $300.00 to $297.00 and set a "neutral" rating for the company in a research note on Friday, July 25th. Eight research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $297.58.

Humana Price Performance

Shares of NYSE HUM opened at $290.66 on Friday. Humana Inc. has a fifty-two week low of $206.87 and a fifty-two week high of $315.35. The stock has a market cap of $34.96 billion, a price-to-earnings ratio of 22.31, a PEG ratio of 1.70 and a beta of 0.42. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95. The firm's 50-day simple moving average is $281.65 and its 200 day simple moving average is $258.97.

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing the consensus estimate of $6.32 by ($0.05). Humana had a net margin of 1.28% and a return on equity of 13.67%. The business had revenue of $32.39 billion during the quarter, compared to the consensus estimate of $31.85 billion. During the same period in the previous year, the business posted $6.96 EPS. Humana's revenue was up 9.6% compared to the same quarter last year. Humana has set its FY 2025 guidance at 17.000- EPS. As a group, research analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be given a $0.885 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $3.54 annualized dividend and a yield of 1.2%. Humana's dividend payout ratio (DPR) is presently 27.17%.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.